(19)
(11) EP 1 180 378 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
09.03.2011 Bulletin 2011/10

(45) Mention of the grant of the patent:
10.11.2010 Bulletin 2010/45

(21) Application number: 01124194.0

(22) Date of filing: 03.03.2000
(51) International Patent Classification (IPC): 
A61M 15/00(2006.01)
A61M 11/02(2006.01)
A61M 11/06(2006.01)
 A61M 15/08(2006.01)
A61M 16/00(2006.01)

(54)

Nasal delivery device

Nasales Verabreichungsgerät

Dispositif d'administration nasale

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 03.03.1999 GB 9904906
19.05.1999 GB 9911686

(43) Date of publication of application:
20.02.2002 Bulletin 2002/08

(60) Divisional application:
10011951.0
10011952.8

(62) Application number of the earlier application in accordance with Art. 76 EPC:
00906570.7 / 1161274

(73) Proprietor: Optinose AS
0349 Oslo (NO)

(72) Inventor:
  • Djupesland, Per Gisle
    0773 Oslo (NO)

(74) Representative: Boden, Keith McMurray et al
Fry Heath & Spence LLP The Gables Massetts Road
Horley Surrey RH6 7DQ
Horley Surrey RH6 7DQ (GB)


(56) References cited: : 
EP-A- 0 634 186
GB-A- 408 856
US-A- 2 470 297
 WO-A-98/53869
US-A- 1 873 160
US-A- 4 919 128
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).